U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07804901) titled 'Asciminib Frontline Risk Adapted' on Aug. 31.
Brief Summary: This is a multi-center, prospective, non-randomized but stratified interventional phase II study of newly diagnosed CML patients in chronic phase. All patients will be treated with asciminib 80 mg QD. Patients with unfavorable risk factors will commence dasatinib 80 mg 5 days/week 4 weeks after start of asciminib. The study will be conducted in Germany.
Study Start Date: Jan. 01, 2027
Study Type: INTERVENTIONAL
Condition:
Chronic Myeloid Leukemia (CML)
Intervention:
DRUG: Dasatinib 80mg QD (5 days per week)
Patients with unfavorable risk factors will commence dasati...